

Lane Michael  
Form 4  
February 19, 2019

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lane Michael

2. Issuer Name and Ticker or Trading Symbol  
IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
02/14/2019

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
Corporate Vice President

C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE  
(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

WESTBROOK, ME 04092

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |   |   |
| Common Stock                    | 02/14/2019                           |  | M                              | 242   | A   | \$ 0   | 3,623 <sup>(1)</sup>                                  | D |
| Common Stock                    | 02/14/2019                           |  | M                              | 188   | A   | \$ 0   | 3,811   | D |
| Common Stock                    | 02/14/2019                           |  | M                              | 221   | A   | \$ 0   | 4,032   | D |
| Common Stock                    | 02/14/2019                           |  | M                              | 212   | A   | \$ 0   | 4,244   | D |
| Common Stock                    | 02/14/2019                           |  | M                              | 197   | A   | \$ 0   | 4,441   | D |

Edgar Filing: Lane Michael - Form 4

|              |            |   |     |   |           |                    |   |           |
|--------------|------------|---|-----|---|-----------|--------------------|---|-----------|
| Common Stock | 02/14/2019 | F | 324 | D | \$ 206.94 | 4,117              | D |           |
| Common Stock | 02/15/2019 | S | 971 | D | \$ 208    | 3,146              | D |           |
| Common Stock |            |   |     |   |           | 592 <sup>(2)</sup> | I | by spouse |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title   | Amount or Number of Shares |
| Non-Qualified Stock Option (right-to-buy)  | \$ 206.94  | 02/14/2019                           |  | M                              | 8,366   | <sup>(3)</sup> 02/13/2029                                | Common Stock  | 8,366                      |
| Incentive Stock Option (right-to-buy)      | \$ 206.94  | 02/14/2019                           |  | M                              | 483   | <sup>(4)</sup> 02/13/2029                                | Common Stock  | 483                        |
| Restricted Stock Unit                      | <sup>(5)</sup>   | 02/14/2019                           |  | M                              | 906   | <sup>(5)</sup> <sup>(5)</sup>                            | Common Stock  | 906                        |
| Restricted Stock Unit                      | <sup>(6)</sup>   | 02/14/2019                           |  | M                              | 242   | <sup>(6)</sup> <sup>(6)</sup>                            | Common Stock  | 242                        |
| Restricted Stock Unit                      | <sup>(7)</sup>   | 02/14/2019                           |  | M                              | 188   | <sup>(7)</sup> <sup>(7)</sup>                            | Common Stock  | 188                        |
| Restricted Stock Unit                      | <sup>(8)</sup>   | 02/14/2019                           |  | M                              | 221   | <sup>(8)</sup> <sup>(8)</sup>                            | Common Stock  | 221                        |
| Restricted Stock Unit                      | <sup>(9)</sup>   | 02/14/2019                           |  | M                              | 212   | <sup>(9)</sup> <sup>(9)</sup>                            | Common Stock  | 212                        |
| Restricted Stock Unit                      | <sup>(10)</sup>  | 02/14/2019                           |  | M                              | 197   | <sup>(10)</sup> <sup>(10)</sup>                          | Common Stock  | 197                        |

# Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                          |       |
|--|---------------|-----------|--------------------------|-------|
|  | Director      | 10% Owner | Officer                  | Other |
| Lane Michael<br>C/O IDEXX LABORATORIES, INC.<br>ONE IDEXX DRIVE<br>WESTBROOK, ME 04092 |               |           | Corporate Vice President |       |

# Signatures

/s/ Lily J. Lu, Attorney-in-Fact for Michael

Lane

02/19/2019

\_\_Signature of Reporting Person

Date

# Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes a total of 48 shares purchased under the Issuer's Employee Stock Purchase Plan on September 28, 2018 and December 31, 2018.
- (2) Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.
- (3) Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020.
- (4) Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant.
- (5) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020.
- (6) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split").
- (7) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split.
- (8) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017.
- (9) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018.
- (10) 9. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019.
- (11) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.